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ABSTRACT
Introduction: Major abdominal surgery leads to a
postoperative systemic inflammatory response, making
it difficult to discriminate patients with systemic
inflammatory response syndrome from those with a
beginning postoperative infectious complication. At
present, physicians have to rely on their clinical
experience to differentiate between the two. Pancreatic
stone protein (PSP) and pancreatitis-associated protein
(PAP), both secretory proteins produced by the
pancreas, are dramatically increased during pancreatic
disease and have been shown to act as acute-phase
proteins. Increased levels of PSP have been detected in
polytrauma patients developing sepsis and PSP has
shown a high diagnostic accuracy in discriminating the
severity of peritonitis and in predicting death in
intensive care unit patients. However, the prognostic
value of PSP/PAP for infectious complications among
patients undergoing major abdominal surgery is
unknown.
Methods and analysis: 160 patients undergoing
major abdominal surgery will be recruited
preoperatively. On the day before surgery, baseline
blood values are attained. Following surgery, daily
blood samples for measuring regular inflammatory
markers (c-reactive protein, procalcitonin, interleukin-6,
tumour necrosis factor-α and leucocyte counts) and
PSP/PAP will be acquired. PSP/PAP will be measured
using a validated ELISA developed in our research
laboratory. Patient’s discharge marks the end of his/her
trial participation. Complication grade including
mortality and occurrence of infectious postoperative
complications according to validated diagnostic criteria
will be correlated with PSP/PAP values. Total intensive
care unit days and total length of stay will be recorded
as further outcome parameters.
Ethics and dissemination: The PSP trial is a
prospective monocentric cohort study evaluating the
prognostic value of PSP and PAP for postoperative
infectious complications. In addition, a comparison
with established inflammatory markers in patients
undergoing major abdominal surgery will be performed
to help evaluate the role of these proteins in predicting
and diagnosing infectious and other postoperative
complications.
Institution ethics board approval ID: KEKZH-Nr.
STV 11-2009.
Trial registration: ClinicalTrials.gov: NCT01258179.
Strengths and limitations of this study
▪ Assessment of the novel sepsis biomarkers
pancreatic stone protein/pancreatitis-associated
protein (PSP/PAP) in an abdominal surgical
study population.
▪ Comparison of PSP/PAP to other acute-phase
reaction proteins, regularly measured in surgical
study populations.
▪ Evaluation of ability of PSP/PAP to predict infec-
tious complications in patients undergoing major
abdominal surgery.
▪ Evaluation of ability of PSP/PAP to predict post-
operative sepsis in patients undergoing major
abdominal surgery (independently and in
comparison with other inflammatory markers).
▪ External validation of PSP/PAP as a sepsis
marker in an independent, prospective patient
cohort.
▪ Limited ability to generalise to other surgical or
medical patient populations.
▪ Limited ability to determine role in guiding treat-
ment decisions.
▪ Non-blinded, non-randomised single-centre
observational cohort study.
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BACKGROUND AND CURRENT KNOWLEDGE
The acute-phase reaction is a systemic, non-speciﬁc
response of the organism to acute inﬂammation and
infection, which also occurs after surgery, and is also
associated with changes in the plasma protein proﬁle.1
Endothelial cells, ﬁbroblasts and inﬂammatory cells such
as macrophages secrete endogenous immune mediators
in the damaged tissue, such as interleukin-1 (IL-1), IL-6,
interferon-γ and tumour necrosis factor-α (TNF-α). In
the presence of cortisol, this results in the induction of
synthesis of various acute-phase proteins stemming from
the liver.2 These include c-reactive protein (CRP), serum
amyloid A (SAA), ﬁbrinogen and the complement C3.3
These proteins can be used as outcome measures of the
acute-phase reaction3 and have been established in clin-
ical practice. Prolonged increase of acute-phase proteins
has been shown to be predictive for postoperative infec-
tions and septic complications.4 5 In addition, studies
have shown that inﬂammatory markers such as TNF,
IL-10 and IL-6 play an important role in the pathogen-
esis of postoperative systemic inﬂammatory response
syndrome (SIRS).6 However, acute-phase proteins are
not synthesised in the liver. It has been shown that the
pancreas increases the production of pancreatic secre-
tory proteins such as pancreatitis-associated protein
(PAP) and the pancreatic stone protein/regenerating
protein (PSP/reg), known as secretory stress proteins
(SSPs).7 8 In previous work, our group has shown an
increased production and secretion of SSPs in stress
induction of a murine pancreatitis-model (WBN/Kob
rat).9 10 Another group was able to demonstrate a correl-
ation between the course of pancreatitis and the induc-
tion of pancreatic SSPs.11 However, it has also been
demonstrated that PAP and PSP are secreted in other
organs, such as the small intestine.12 13 PAP was
increased under inﬂammatory conditions of the small
intestine, especially in coeliac disease.13 More recently,
it was demonstrated that PAP and its associated
metalloproteinases are involved in wound healing
processes.14
In a clinical study in polytrauma patients, a signiﬁcant
increase of PSP was observed in those patients who
developed infections or sepsis.15 The same study showed
that PSP binds and activates neutrophils, thus acting as
an acute-phase protein. The concept that PSP is an early
marker of sepsis was further conﬁrmed in subsequent
studies on patient populations admitted to the ICU.16–18
Therefore, it seems clear that PAP and PSP play an
important role in various inﬂammatory events, not only
in pancreatitis but also in sepsis subsequent to other
inﬂammatory diseases. However, until now, no peri-
operative study exists, which looks at the value of these
proteins and their role as postoperative inﬂammatory
serum markers following major abdominal surgery. In
addition, differentiating between a simple inﬂammatory
response and a true infectious complication following
abdominal surgery still remains a challenge in clinical
practice. Here, PAP and PSP/reg may provide valuable
information and aid in differentiating between both
events in the postoperative setting.
METHODS AND STUDY DESIGN
The PSP study is a prospective, monocentric cohort
study evaluating the role of PSP and PAP as new markers
for postoperative infectious complications following
abdominal surgery. Our study population will consist of
patients undergoing liver (n=30), pancreas (n=30),
upper gastrointestinal tract (n=30) and lower gastrointes-
tinal tract (n=30) surgery as well as patients undergoing
emergency abdominal procedures (n=20) and patients
undergoing combined renal/pancreas transplantation
(n=10). A total of 160 patients will be recruited. To
ensure adequate data quality, an interim analysis will be
performed once 80 patients have been recruited.
A power analysis will be performed based on the actual
and precise data collected. At interim analysis, the
potential need to modify the sample size will be investi-
gated. If the external data monitoring committee sug-
gests any changes based on these calculations, the
principal investigators will decide on the feasibility of
the potential changes and submit a formal addendum to
the ethics committee. Unless ﬁrst approved by the local
ethics committee, no changes will be made to the proto-
col or study design. Any changes to the protocol
approved by the ethics committee will be updated at
clinicaltrials.gov [NCT01258179].
STUDY OBJECTIVES AND ENDPOINTS
Study objectives
▸ To determine serum levels of PAP and PSP/reg
attained from venous samples of patients undergoing
major abdominal surgery.
▸ To determine an association between PSP/PAP
expression and current, routinely measured inﬂam-
matory markers (CRP, procalcitonin, TNF-α, IL-6,
white cell count and thrombocyte count) and
compare these with regard to predicting post-
operative complications.
▸ To determine whether PSP/PAP levels correlate with
postoperative infectious complications and general
postoperative complications as graded by the vali-
dated Clavien-Dindo classiﬁcation for postoperative
surgical complications.19
▸ To determine whether PSP/PAP can be used as a
predictive marker for postoperative infectious compli-
cations and sepsis.
Endpoints
Primary endpoint
▸ Association of PSP/PAP expression values with
patients experiencing infectious postoperative compli-
cation according to the SIRS and Sepsis Criteria of
the German Interdisciplinary Association of Intensive
and Emergency Medicine (DIVI) and the ACCP/
SCCM Consensus Conference Criteria.20 21
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Secondary endpoints
▸ Correlation/comparison of PSP/PAP expression
values to current markers of inﬂammation in patients
undergoing major abdominal surgery.
▸ Association of PSP/PAP expression values with overall
complication grade according to the Clavien-Dindo
score for postoperative complications which includes
mortality.
▸ Association of PSP/PAP expression values with overall
postoperative infectious complications and the correl-
ation between PSP/PAP expression values and
changes/alterations to management of postoperative
complications.
▸ Value of serum PSP/PAP levels at time of admission
to intensive care unit (ICU) to predict infection/
sepsis outcome during postoperative course including
total ICU days and total length of stay.
Inclusion criteria
▸ Age >18 years.
▸ Patients scheduled for abdominal surgery including
liver, pancreas, upper gastrointestinal tract, lower
gastrointestinal tract procedures, patients planned for
combined kidney-renal transplantation as well as
patients requiring emergency abdominal procedures.
▸ Patients able to provide informed consent.
Exclusion criteria
▸ Age <18 years.
▸ Patients unable to provide informed consent.
SIRS and sepsis criteria
Systemic inflammatory response syndrome
▸ Fever ≥38.0°C or hypothermia ≤36.0°C measured
rectal, intravascular or within the bladder.
▸ Tachycardia ≥90/min.
▸ Tachypnoea ≥20/min or hyperventilation (measured
via arterial blood gas analysis showing PaCO2
≤4.3 kPa/33 mm Hg).
▸ Leukocytosis ≥12 000/mm3 or leucopenia ≤4000/mm3
or ≥10% of immature neutrophils on differential blood
analysis.
At least two of the aforementioned criteria must be ful-
ﬁlled to diagnose SIRS.20 21
Sepsis
▸ Proven microbiological infection (eg, positive blood
cultures).
▸ At least two of the above mentioned SIRS criteria.
DATA COLLECTION AND STATISTICAL METHODOLOGY
Data collection
Patients will be recruited on the day before surgery or
on admission for emergency abdominal surgery. They
will be evaluated for inclusion criteria and informed
about the study as well as the possibility of study partici-
pation. Once the informed consent form has been read,
understood and signed, baseline blood samples will be
obtained and sent in for routine as well as separate ana-
lysis of PSP/PAP levels. Following surgery, daily blood
samples will be obtained and analysed for the sample
values. Blood samples will be marked with patient’s
names, date of birth and date of sample extraction for
identiﬁcation purposes during transportation to our
laboratory. However, following arrival of the blood
sample in our laboratory and prior to processing, all
patients’ information will be modiﬁed to allow for
anonymous biobanking and study participation.
If postoperative complications occur, they will be docu-
mented in the patient’s chart by the treating physicians
according to the Clavien-Dindo classiﬁcation of post-
operative complications, as is usual clinical practice in our
department. In the presence of infectious complications,
evaluation for the presence of SIRS/sepsis according to
the aforementioned criteria will occur. If criteria for SIRS
are fulﬁlled, blood cultures will be taken according to the
aforementioned guidelines to document septic complica-
tions. Patient demographic data will be collected via chart
analysis by the principal investigator and other participat-
ing investigators and will be documented in a central, pro-
spective database (see online supplementary ﬁle 1). Study
participation ends with patient discharge (ﬁgure 1).
No commercial analysis kit exists for PSP/PAP analysis.
Therefore, separate blood samples will be sent to our
in-house research team, where direct protein detection
through a validated ELISA is performed.22 Excessive
material will be stored and catalogued in a central,
anonymous biobank (−80°C fridge).
Statistical methods
We will compare continuous variables with the Student t,
Mann-Whitney U, one-way analysis of variance and
Kruskal-Wallis tests. Differences among proportions
derived from categorical data will be assessed using the
Fisher’s exact or the Pearson χ2 tests where appropriate.
Paired statistics will be used where appropriate. All p
values will be two-sided and statistical signiﬁcance will be
if p≤0.05. Sensitivity, speciﬁcity, accuracy, positive predict-
ive value, negative predictive value, positive likelihood
ratio, negative likelihood ratio, Yuden’s index, diagnostic
OR and the receiver operator characteristic curve will be
calculated. Where appropriate, Kaplan-Meier survival
curves and survival comparison using the log-rank test
will be performed. Where appropriate, data will be pre-
sented as mean (SD), median (IQR) and ORs (95% CI).
We will duplicate the blood samples to analyse reproduci-
bility of PSP/PAP measurements and assess the variability
by the Pearson’s correlation coefﬁcient. We will use SPSS
Statistics V.20 (SPSS: an IBM company, Chicago Illinois,
2011) to perform statistical analysis.
STUDY SITE
Department of Surgery, University Hospital Zurich,
Raemistrasse 100, CH-8091 Zurich, Switzerland
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STUDY STARTING AND ESTIMATED COMPLETION DATE
First patient recruitment for this study occurred follow-
ing the approval by the local ethics committee in
February 2011. Expected study completion date will be
December 2014.
ETHICS
This study is conducted in accordance with the princi-
ples of the Declaration of Helsinki and ‘good clinical
practice’ guidelines.
DISCUSSION
Until now, no perioperative studies exist looking at the
value and role of PAP and PSP/reg as postoperative
inﬂammatory serum markers in patients having major
abdominal surgery, although it has been demonstrated
that PSP/PAP play an important role in various inﬂam-
matory events models.7 9 10 13 14 In addition, many
serum markers have been studied in the hope of disco-
vering new biomarkers, which will aid in recognising
sepsis.3–5 23 However, until now no single test exists,
which enables physicians to diagnose sepsis and they,
therefore, still have to rely on a combination of physical
examination and laboratory ﬁndings as well as clinical
judgement, thereby potentially delaying adequate treat-
ment. This is crucial, as septic complications following
abdominal surgery are treacherous and require early
diagnosis and aggressive management due to their high
rate of morbidity and mortality.24 25 Here, PSP/PAP may
serve as novel markers for postoperative sepsis, to facili-
tate early diagnosis of sepsis and thereby hopefully
directing resources to those patients at highest risk for
death due to septic complications.
CONCLUSION
The PSP study is a prospective, monocentric cohort
study evaluating the role of PSP and PAP as new markers
for postoperative infectious complications following
abdominal surgery.
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Figure 1 Flowchart of patient
recruitment and study
participation. PAP,
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PSP, pancreatic stone protein.
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